Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.

hepatocellular carcinoma sarcopenia skeletal muscle index sorafenib

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 14 02 2024
revised: 29 02 2024
accepted: 05 03 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

Sarcopenia has been associated with poor outcomes in patients with cirrhosis and hepatocellular carcinoma. We investigated the impact of sarcopenia on survival in patients with advanced hepatocellular carcinoma treated with Sorafenib. A total of 328 patients were retrospectively analyzed. All patients had an abdominal CT scan within 8 weeks prior to the start of treatment. Two cohorts of patients were analyzed: the "Training Group" (215 patients) and the "Validation Group" (113 patients). Sarcopenia was defined by reduced skeletal muscle index, calculated from an L3 section CT image. Sarcopenia was present in 48% of the training group and 50% of the validation group. At multivariate analysis, sarcopenia (HR: 1.47,

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Sarcopenia has been associated with poor outcomes in patients with cirrhosis and hepatocellular carcinoma. We investigated the impact of sarcopenia on survival in patients with advanced hepatocellular carcinoma treated with Sorafenib.
METHODS METHODS
A total of 328 patients were retrospectively analyzed. All patients had an abdominal CT scan within 8 weeks prior to the start of treatment. Two cohorts of patients were analyzed: the "Training Group" (215 patients) and the "Validation Group" (113 patients). Sarcopenia was defined by reduced skeletal muscle index, calculated from an L3 section CT image.
RESULTS RESULTS
Sarcopenia was present in 48% of the training group and 50% of the validation group. At multivariate analysis, sarcopenia (HR: 1.47,

Identifiants

pubmed: 38539416
pii: cancers16061080
doi: 10.3390/cancers16061080
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Maurizio Biselli (M)

Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40124 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.

Nicola Reggidori (N)

Department of Internal Medicine, Ospedale per gli Infermi di Faenza, 48018 Faenza, Italy.

Massimo Iavarone (M)

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Matteo Renzulli (M)

Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Lorenzo Lani (L)

Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40124 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.

Alessandro Granito (A)

Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.
Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Fabio Piscaglia (F)

Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.
Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Stefania Lorenzini (S)

Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40124 Bologna, Italy.

Eleonora Alimenti (E)

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Giulio Vara (G)

Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Paolo Caraceni (P)

Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40124 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.

Angelo Sangiovanni (A)

Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.

Massimo Marignani (M)

Division of Gastroenterology and Hepatology, Ospedale Regina Apostolorum, 00041 Albano Laziale, Italy.

Elia Gigante (E)

Service d'Hépato-Gastroentérologie et de Cancérologie Digestive, Hôpital Robert Debré, Université Reims-Champagne-Ardenne, 51092 Reims, France.

Nicolò Brandi (N)

Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Annagiulia Gramenzi (A)

Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40124 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.

Franco Trevisani (F)

Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40124 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40124 Bologna, Italy.

Classifications MeSH